Professor Maher Gandhi
|Professor Maher Gandhi|
Leukaemia Foundation Queensland Chair in Blood Cancer Research
Senior Staff Specialist, Department of Haematology, Princess Alexandra Hospital
Professor Maher Gandhi has established an international reputation studying immunity and identification of novel biomarkers in lymphoma. His research aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. Lymphomas studied include Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and virus associated lymphomas. A broad range of approaches are utilised including genomics, molecular and cellular biology techniques and functional immunoassays.
Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He obtained a PhD in immunology at Cambridge University. In 2003 he moved to Brisbane, working as a Senior Staff Specialist in the Haematology / Oncology Department of the Princess Alexandra Hospital, and established his own laboratory group at QIMR. He is Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. He was privileged to serve as Chair of the Metro South Human Research Ethics Committee between 2011-2014. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, and took up his current role Head of the Blood Cancer Research Laboratory at the Diamantina Institute in 2014.
Phone: +61 7 3443 8026
Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples. Khamenehfar, Avid, Gandhi, Maher K., Chen, Yuchun, Hogge, Donna E. and Li, Paul C. H. (2016) Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples. Analytical Chemistry, 88 11: 5680-5688. doi:10.1021/acs.analchem.5b04446
The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Jones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R. and Gandhi, M. K. (2016) The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 183 2: 206-220. doi:10.1111/cei.12716
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Taylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2015) Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Nephrology Dialysis Transplantation, 30 10: 1774-1779. doi:10.1093/ndt/gfv260
Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Scott, Linda M. and Gandhi, Maher K. (2015) Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Reviews, 29 6: 405-415. doi:10.1016/j.blre.2015.06.002
Fine mapping of the 15q21 region implicate TP53BP1 and B2M in the lymphomagenesis of Follicular and Diffuse Large B-Cell lymphomas. Carlos Aya-Bonilla, Emily Camilleri, Miles Benton, Larisa M Haupt, Paula Marlton, Rod A Lea, Maher K Gandhi and Lyn R. Griffiths. Carcinogenesis & Mutagenesis. 2014 May 21;15:390.
In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL). Carlos A Aya-Bonilla, Emily Camiller, Larisa M Haupt, Rod A Lea, Maher K Gandhi and Lyn R Griffiths. BMC Genomics. 2014; 15(1): 390.
A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns of EBV-association. S. E. K. Fink; M. K. Gandhi; J. Nourse; C. Keane; K. Jones; P. Crooks; K. Jöhrens; A. Korfel; H. Schmidt; S. Neumann; A. Tiede; U. Jäger; U. Dührsen; R. Neuhaus; M. Dreyling; K. Borchert; T. Südhoff; H. Riess; I. Anagnostopoulos; R. U. Trappe. American Journal of Transplantation. 2014 Nov;14(11):2577-87
A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsed or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study). Huyen Tran, Tim Brighton, Andrew Grigg, Simon McRae, Joanna Dixon, Daniel Thurley, Maher K. Gandhi,Matt Truman, Paula Marlton, and John Catalano. British Journal of Haematology. 2014 Oct;167(2):243-51.
Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma. Kimberley Jones, Jamie P. Nourse, Colm Keane, Atul Bhatnagar, and Maher K. Gandhi. Clinical Cancer Research. 2014 Jan 1;20(1):253-64.
A new frontier in haematology - combining pharmacokinetics with pharmacodynamic factors to improve choice and dose of drug. David Arpon, Maher K. Gandhi, Jenny Martin. British Journal of Clinical Pharmacology. 2014 Aug;78(2):274-81.
The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. L A. Seymour, JP. Nourse, P Crooks, L Wockner, R Bird, H Tran & MK. Gandhi. Tissue Antigens. 2014 Mar;83(3):154-60.
FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorder. Heiner Zimmermann, Theresa Weiland, Jamie Nourse, Maher Gandhi, Petra Reinke, Ruth Neuhaus, Mohsen Karbasiyan, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Ralf Trappe and Stephan Oertel Clinical and Developmental Immunology. Journal of Immunology Research. 2014;2014:264723.
Serum CD163 and TARC as circulating biomarkers in Hodgkin lymphoma. Kimberley Jones, Louise Seymour, Maher K. Gandhi. Book Chapter "Biomarkers in Disease: Methods, Discoveries and Applications." Accepted 2014.
CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy Keane, Colm, Gill, Devinder, Vari, Frank, Cross, Donna, Griffiths, Lynn and Gandhi, Maher (2013) American Journal of Hematology, 88 4: 273-276.
- Novel regulators of cellular immunity in Diffuse Large B-cell Lymphoma
- The interaction between environmental and genetic factors in Hodgkin lymphoma
- Prognostic and disease response biomarkers
- Mechanisms of action of immune effector cells
- The development and characterization of a novel laboratory model of B-cell differentiation and lymphomagenesis.
We are keen to take on enthusiastic postgraduate students for honours, masters, doctoral studies and medical students looking to expand their skills by undertaking an MPhil or PhD. We provide opportunities and hands on training for students to develop a range of proficiencies in immunological and biological techniques, that are relevent for their future careers in the field of haematological malignancies.
Frequently, opportunities are provided for students to travel to present their work at national and international conferences, and our students have an extremely high success rate in being selected for oral presentations.
If you are interested in finding out more, please email the Professor Maher Gandhi and provide your CV and academic record.
Students must fulfil standard University of Queensland entry requirements. Overseas elective students are also encouraged to apply.